Please assess the completion status of the following clinical trial:

Trial Title: n-3 Polyunsaturated Fatty Acids (PUFAs) in the Prevention of Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* persistent Atrial Fibrillation (AF) lasting \> one month~* history of at least one AF relapse after previous electrical or Pharmacological cardioversion~Exclusion Criteria:~* left atrium size \> 6 cm~* severe valvulopathy~* myocardial infarction during the previous 6 months~* unstable angina~* NYHA heart failure class IV or hemodynamic instability~* cardiac surgery during the previous 3 months~* significant pulmonary thyroid and hepatic disease~* contraindications to treatment with amiodarone or RASS inhibitors~* chronic renal dysfunction~* QT \> 480 msec in the absence of bundle-branch block~* bradycardia \< 50 b/min~* diagnosis of paroxysmal AF~* hyperkalemia~* pregnancy~* any disease or other medical treatment that, in the opinion of the investigators, could interfere with the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- n-3 PUFAs (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).